Revelation Biosciences reported a net loss of $3.3 million ($0.87 per share) for the three months ended June 30, 2026, compared to a net loss of $2.4 million in the prior year period. For the six-month period, the company recorded a net loss of $6.3 million ($3.41 per share), up from $4.5 million in 2025. Cash and cash equivalents increased to $11.5 million as of June 30, 2026, from $10.7 million at year-end 2025, primarily due to proceeds from a January 2026 warrant inducement. The company stated that its current liquidity is sufficient to fund operations through the first quarter of 2027. Clinical development continues with Phase 2/3 startup activities for Gemini in acute kidney injury patients, targeting enrollment by year-end. Revelation Biosciences is a clinical-stage life sciences company developing innovative inflammation-based treatments.

Revelation Biosciences, Inc. adopted a stockholder rights plan (poison pill) poison pill and entered into a Rights Agreement with Continental Stock Transfer & Trust Co. to prevent an acquiring person from reaching 10% ownership. The company declared a dividend of one preferred share purchase right per common stock share, with a record date of July 21, 2026. Revelation Biosciences, Inc. is a biotechnology company focused on developing immune-based therapies.

Revelation Biosciences, Inc. stockholders approved a proposal to grant the Board of Directors discretionary authority to effect one or more reverse stock splits between a ratio of 1-for-2 and 1-for-250 within one year of June 24, 2026. The company also amended its bylaws to include universal proxy rules, a formal definition of "Cause" for director and officer removal, and an interim succession framework for the CEO and CFO. Revelation Biosciences, Inc. is a biotechnology company focused on developing immune-based therapies.